Related Experiment Videos
Acanthamoeba sclerokeratitis: treatment with systemic immunosuppression
Graham A Lee1, Trevor B Gray, John K G Dart
1Moorfields Eye Hospital, London, England UK.
Ophthalmology
|June 5, 2002
Summary
Severe Acanthamoeba sclerokeratitis (ASK) often requires systemic immunosuppression for management. This immune-mediated condition can lead to significant vision loss, but immunosuppression helps control inflammation and preserve ocular tissue.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Immunology
Background:
- Acanthamoeba keratitis (AK) is a severe microbial infection of the cornea.
- Acanthamoeba sclerokeratitis (ASK) is an uncommon, sight-threatening complication of AK.
- Conventional topical treatments are often insufficient for managing severe ASK.
Observation:
- This study reviewed 19 patients with severe ASK unresponsive to standard care.
- Patients received systemic immunosuppression to control inflammation and pain.
- Mean treatment duration was 7.2 months, with a mean follow-up of 24.3 months.
Findings:
- Systemic immunosuppression was required in 19 patients (20 eyes) with severe ASK.
- Visual acuity at presentation was poor in 55% of eyes (counting fingers or worse).
- At final follow-up, 40% of eyes had vision of counting fingers or worse, while 30% achieved 20/40 or better.
Implications:
- ASK appears to involve an immune-mediated inflammatory response.
- Systemic immunosuppression is a viable strategy for managing severe, refractory ASK.
- Early intervention with immunosuppression may improve visual outcomes in severe ASK cases.